This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cicatrix Cream in Cutaneous Groves

This study has been completed.
Information provided by:
Catalysis SL Identifier:
First received: November 20, 2009
Last updated: December 7, 2010
Last verified: December 2010
The purpose of the study is to assess the effect of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of cutaneous grooves. The duration of this phase 2 clinical trial will be 4 months.

Condition Intervention Phase
Cutaneous Groves Other: Cicatrix cream Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect the Cicatrix Cream in Cutaneous Groves Treatment

Resource links provided by NLM:

Further study details as provided by Catalysis SL:

Primary Outcome Measures:
  • They are the cutaneous grooves, being Observed the reduction of the number of the lesions monthly. [ Time Frame: 4 month ]

Secondary Outcome Measures:
  • Extension of the groves and the reduction of these expressed in centimetres [ Time Frame: 4 months ]
  • Adverse effects [ Time Frame: 4 months ]

Estimated Enrollment: 50
Study Start Date: September 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Cicatrix cream
Other: Cicatrix cream

We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.

The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application.


Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent

Exclusion Criteria:

  • Patient that refer manifestations of high sensibility to the medication or to some of the components of the product.
  • Patient that don't want to participate in the study.
  • Patient not very cooperative.
  • Responsible family not very cooperative.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01018212

Pediatric Hospital Juan Manuel Marquez
Havana City, Havana, Cuba, 10400
Sponsors and Collaborators
Catalysis SL
Principal Investigator: Fernanda Pastrana, MD Pediatric Hospital Juan Manuel Marquez
  More Information

Responsible Party: Fernanda Pastrana, Pediatric Hospital Juan Manuel Márquez Identifier: NCT01018212     History of Changes
Other Study ID Numbers: CAT-0902-CU
Study First Received: November 20, 2009
Last Updated: December 7, 2010

Keywords provided by Catalysis SL:
Cutaneous Groves

Additional relevant MeSH terms:
Pathologic Processes processed this record on August 18, 2017